Uric acid
-
Uric acid
structure -
-
CAS No:
69-93-2
-
Formula:
C5H4N4O3
-
Chemical Name:
Uric acid
-
Synonyms:
1H-Purine-2,6,8(3H)-trione,7,9-dihydro-;Uric acid;7,9-Dihydro-1H-purine-2,6,8(3H)-trione;Lithic acid;Purine-2,6,8(1H,3H,9H)-trione;2,6,8-Trioxypurine;1H-Purine-2,6,8-triol;2,6,8-Trioxopurine;2,6,8-Trihydroxypurine;NSC 3975;Uric acid hyperuricemia;2,3,6,7,8,9-Hexahydro-1H-purine-2,6,8-trione;530-13-2;13154-20-6;33278-42-1;34318-07-5;42911-28-4;42911-27-3;42911-25-1
- Categories:
-
CAS No:
Description
Uric acid is an endogenous antioxidant that scavenges reactive oxygen species (ROS) including singlet oxygen, oxygen radicals, and peroxynitrite.
Solid
7,9-dihydro-1H-purine-2,6,8(3H)-trione is an oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8. It has a role as a human metabolite, an Escherichia coli metabolite and a mouse metabolite. It is a tautomer of a 2,6-dihydroxy-7,9-dihydro-8H-purin-8-one, a 9H-purine-2,6,8-triol, a 7H-purine-2,6,8-triol, a 1H-purine-2,6,8-triol and a 5,7-dihydro-1H-purine-2,6,8(9H)-trione.|Uric acid is the last product of purine metabolism in humans. The formation of uric acid is through the enzyme xanthine oxidase, which oxidizes oxypurines. Normally a small amount of uric acid is present in the body, but when there is an excess amount in the blood, called hyperuricemia, this can lead to gout and formation of kidney stones. As a therapeutic agent, it is known that uric acid is increased in response to oxidative stress, and as such, uric acid acts as an antioxidant. At present (August 2013), there is no approved formulation or indication for uric acid. In one country, Spain, uric acid is an investigational drug in a phase 3 trial studying its effects as an adjunct to alteplase in acute ischemic stroke.|Uric Acid is a white tasteless odorless crystalline product of protein metabolism, found in the blood and urine, as well as trace amounts found in the various organs of the body. It can build up and form stones or crystals in various disease states.|An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
Uric acid Basic Attributes
168.11
168.11
156158
200-720-7
268B43MJ25
3975
DTXSID3042508
C62652
2933990090
Characteristics
99.3
-2.17
White to off-white crystalline
1.003-1.010 g/cm3
310 °C (decomp)
863ºC at 760 mmHg
475.7ºC
1.721
soluble in 1M sodium hydroxide solution. Slightly soluble in water. Insoluble in ether and alcohol.
Store at RT.
5.4None
131 Ų [M+H]+ [CCS Type: DT, Method: stepped-field]|143.5 Ų [M+Na]+ [CCS Type: DT, Method: stepped-field]|127.08 Ų [M-H]- [CCS Type: DT, Method: stepped-field]|130.7 Ų [M+H]+ [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|125.5 Ų [M-H]- [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|126.93 Ų [M-H]- [CCS Type: DT, Method: stepped-field]|126.2 Ų [M-H]-
Safety Information
NONH for all modes of transport
3
33-36/37/38
24/25-36-26
YU7050080
Xi
Stable. Incompatible with acids, bases, oxidising agents.
Not Classified
Drug Information
At present (August 2013), there is no approved indication for uric acid. The potential therapeutic use for uric acid is as an adjunct in acute ischemic stroke.
Uric acid is a strong reducing agent (donates electrons) and an antioxidant. Normally in humans, one of the main antioxidants in plasma is uric acid. Several animal studies have found that animals given exogenous uric acid within 3 hours after a stroke had decreased infarct volume, improved neurologic function, and diminished inflammatory responses providing evidence for the neuroprotective effects of uric acid. In some early human studies, uric acid has so far shown similar neuroprotective effects, in both the cortex and subcortex areas, due to its antioxidant effects such as decreased lipid peroxidation, and there appears to be no significant toxicities.
Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)
Uric acid is eliminated by the kidneys.
In higher primates and humans, the enzyme, uricase, is absent, and thus uric acid is not further metabolized and is excreted. In all other mammals, uric acid is metabolized by uricase to allantoin, which is then excreted.
The exact mechanism of action for uric acid's antioxidant effects have not yet been elucidated.
2,6,8-Trihydroxypurine
Uric acid Use and Manufacturing
A xanthine oxidase product.
1H-Purine-2,6,8(3H)-trione, 7,9-dihydro-: ACTIVE
Cosmetics -> Buffering; Skin conditioning
Computed Properties
Molecular Weight:168.11
XLogP3:-1.9
Hydrogen Bond Donor Count:4
Hydrogen Bond Acceptor Count:3
Exact Mass:168.02834000
Monoisotopic Mass:168.02834000
Topological Polar Surface Area:99.3
Heavy Atom Count:12
Complexity:332
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes
Recommended Suppliers of Uric acid
-
CN
1 YR
Business licensedTrader Supplier of pregabalin,Tirzepatide,Retatrutide,Food Additives,semaglutide,Cosmetics material,Food additive,Chemical intermediate,Active pharmaceutical ingredientsInquiryUnit Price: $1 /KG FOBCAS No.: 69-93-2Grade: USP / EP / BP / JP GradeContent: 99.9% -
CN
5 YRS
Business licensedTrader Supplier of Intermediates,Building blocks,API,Silicones,Peptides,Lab chemicals,Biochemicals,Pharmaceuticals,Screening Compounds,Food Additives
Learn More Other Chemicals
-
3,5-DIBROMO-2-[[[(3,5-DINITROBENZOYL)AMINO]THIOXOMETHYL]AMINO]-BENZOIC ACID
535965-38-9
-
3,5-DIBROMO-2-[[[[(2-CHLOROPHENOXY)ACETYL]AMINO]THIOXOMETHYL]AMINO]-BENZOIC ACID
532386-89-3
-
3,5-DIBROMO-2-[[[(4-METHYL-3-NITROBENZOYL)AMINO]THIOXOMETHYL]AMINO]-BENZOIC ACID
532943-48-9
-
3,5-DIBROMO-2-[[[[3-(2-FURANYL)-1-OXO-2-PROPENYL]AMINO]THIOXOMETHYL]AMINO]-BENZOIC ACID Formula
586392-09-8
-
3,5-DIBROMO-2-[[[[(2-METHYLPHENOXY)ACETYL]AMINO]THIOXOMETHYL]AMINO]-BENZOIC ACID Formula
531548-30-8
-
2-(1,8-dibromo-16,18-dioxo-17-azapentacyclo[6.6.5.0~2,7~.0~9,14~.0~15,19~]nonadeca-2,4,6,9,11,13-hexaen-17-yl)benzoic acid Formula
333340-54-8
-
3,5-DIBROMO-2-[[[[3-(PHENOXYMETHYL)BENZOYL]AMINO]THIOXOMETHYL]AMINO]-BENZOIC ACID Structure
586393-79-5
-
3,5-DIBROMO-2-[[[(4-CHLOROBENZOYL)AMINO]THIOXOMETHYL]AMINO]-BENZOIC ACID Structure
531530-32-2
-
What is 2-Cyclopentyl-3-(2,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-oxo-4-isoquinolinecarboxylic acid
400073-92-9
-
What is 9-Octadecenoic acid (9Z)-, compd. with N,N-dimethylcyclohexanamine (1:1)
65122-23-8